NASDAQ:JSPR Jasper Therapeutics Q3 2024 Earnings Report $0.71 +0.02 (+3.23%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Jasper Therapeutics EPS ResultsActual EPS-$1.24Consensus EPS -$1.09Beat/MissMissed by -$0.15One Year Ago EPSN/AJasper Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJasper Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time7:30AM ETUpcoming EarningsJasper Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jasper Therapeutics Earnings HeadlinesWall Street Zen Upgrades Jasper Therapeutics (NASDAQ:JSPR) to HoldAugust 29, 2026 | americanbankingnews.comAnalysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $8.17August 27, 2026 | americanbankingnews.comLabor Day Warning: The secret that called 1929 is flashing something newIn 1929, a young researcher named Irving Weiss spotted warning signs Wall Street ignored - then watched the Dow crash nearly 13% in a single day, followed by another 12% drop the next. His research became Weiss Ratings, a system The Wall Street Journal ranked number one for investment performance. It also called the Dot-Com Bust, the 2008 crisis, and the 2020 crash. Now the system is flagging a possible shift in the back half of 2026, separating stocks it flags as vulnerable from those positioned to climb.September 4 at 1:00 AM | Weiss Ratings (Ad)Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deJasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals AcquisitionAugust 14, 2026 | quiverquant.comQJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 14, 2026 | globenewswire.comSee More Jasper Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email. Email Address About Jasper TherapeuticsJasper Therapeutics (NASDAQ:JSPR) (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine. Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation. In parallel, Jasper is advancing JN-6000, an extended-release formulation of tacrolimus aimed at reducing the toxicity and dosing complexities associated with conventional immunosuppressive regimens. The company is also investigating JN-403, a small-molecule agent intended to prevent and treat vaso-occlusive crises in sickle cell disease. Since its founding, Jasper Therapeutics has established collaborations with leading academic institutions and biotechnology partners to support its clinical programs and expand its platform capabilities. The company is headquartered in Tarrytown, New York, and maintains research activities in key U.S. biotech hubs. Jasper’s leadership team brings together expertise in translational medicine, clinical development, and regulatory affairs to guide its efforts from early-stage discovery through pivotal studies. With a strategic focus on leveraging immunological insights to design targeted therapies, Jasper Therapeutics aims to deliver novel treatment options for patients experiencing life-threatening disorders. Its ongoing clinical trials and preclinical initiatives reflect a commitment to advancing scientific innovation in areas where current therapeutic choices are limited.View Jasper Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
